NCT06481475View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

PHASE2RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

YY003

Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.

BIOLOGICAL

Vehicle Control

Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.

Trial Locations (3)

2217

RECRUITING

St George Dermatology & Skin Cancer Centre, Sydney

3053

RECRUITING

Skin Health Institute, Melbourne

3141

RECRUITING

Dermatology Institute of Victoria, Melbourne

All Listed Sponsors
lead

Chongqing Claruvis Pharmaceutical Co., Ltd.

INDUSTRY